Benchmark Response (BMR) Values for In Vivo Mutagenicity Endpoints
Open Access
- 4 April 2025
- journal article
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 66 (4) , 172-184
Abstract
The benchmark dose (BMD) approach constitutes the most effective and pragmatic strategy for the derivation of a point of departure (PoD) for comparative potency analysis, risk assessment, and regulatory decision‐making. There is considerable controversy regarding the most appropriate benchmark response (BMR) for genotoxicity endpoints. This work employed the Slob (2017) Effect Size (ES) theory to define robust BMR values for the in vivo transgenic rodent (TGR) and Pig‐a mutagenicity endpoints. An extensive database of dose–response data was prepared and curated; BMD analyses were used to determine endpoint‐specific maxima (i.e., parameter c) and within‐group variance (i.e., var). Detailed analyses investigated the dependence of var on experimental factors such as tissue, administration route, treatment duration, and post‐exposure tissue sampling time. The overall lack of influence of these experimental factors on var permitted the determination of typical values for the endpoints investigated. Typical var for the TGR endpoint is 0.19; the value for the Pig‐a endpoint is 0.29. Endpoint‐specific var values were used to calculate endpoint‐specific BMR values; the values are 47% for TGR and 60% for Pig‐a. Endpoint‐specific BMR values were also calculated using the trimmed distribution of study‐specific standard deviation (SD) values for concurrent controls. Those analyses yielded endpoint‐specific BMR values for the TGR and Pig‐a endpoints of 33% and 58%, respectively. Considering the results obtained, and the in vivo genetic toxicity BMR values noted in the literature, we recommend a BMR of 50% for in vivo mutagenicity endpoints. The value can be employed to interpret mutagenicity dose–response data in a risk assessment context.Keywords
Funding Information
- Rijksinstituut voor Volksgezondheid en Milieu (I/133002/02/DR)
- Health Canada
This publication has 49 references indexed in Scilit:
- Impact of sampling time on the detection of mutations in rapidly proliferating tissues using transgenic rodent gene mutation models: A reviewEnvironmental and Molecular Mutagenesis, 2022
- Permitted daily exposure limits for noteworthy N‐nitrosaminesEnvironmental and Molecular Mutagenesis, 2021
- Genotoxicity as a toxicologically relevant endpoint to inform risk assessment: A case study with ethylene oxideEnvironmental and Molecular Mutagenesis, 2020
- Quantitative Interpretation of Genetic Toxicity Dose‐Response Data for Risk Assessment and Regulatory Decision‐Making: Current Status and Emerging PrioritiesEnvironmental and Molecular Mutagenesis, 2019
- Pig‐a gene mutation databaseEnvironmental and Molecular Mutagenesis, 2019
- Quantitative differentiation of whole smoke solution‐induced mutagenicity in the mouse lymphoma assayEnvironmental and Molecular Mutagenesis, 2017
- Comparing BMD‐derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assayEnvironmental and Molecular Mutagenesis, 2017
- Acrylamide‐induced carcinogenicity in mouse lung involves mutagenicity: cII gene mutations in the lung of big blue mice exposed to acrylamide and glycidamide for up to 4 weeksEnvironmental and Molecular Mutagenesis, 2015
- Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessmentEnvironmental and Molecular Mutagenesis, 2014
- Genotoxicity of acrylamide and its metabolite glycidamide administered in drinking water to male and female Big Blue miceEnvironmental and Molecular Mutagenesis, 2005